ArticleFrontiers in immunology2025
Incidence trends and survival analysis of enteropathy-associated T-cell lymphoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enteropathy-associated T-cell lymphoma (EATL) is a rare, aggressive form of T-cell non-Hodgkin lymphoma, primarily affecting the small intestine. Due to its extremely low incidence and poor prognosis, studies on EATL are limited. This study aims to analyze the incidence trends, prognostic factors, and survival outcomes of EATL using the SEER database. Methods: We analyzed the incidence trends of EATL using SEER data from 2000 to 2021 and performed multivariate Cox regression to identify independent prognostic factors. Conditional survival (CS) analysis was performed to evaluate survival outcomes, and a CS-nomogram was developed to predict 1-, 3-, and 5-year overall survival (OS) and 5-year CS. Results: The age-adjusted incidence rate of EATL was 0.014 per 100,000, showing a significant upward trend (APC 2.63). Multivariate analysis identified age, tumor site, tumor stage, surgery, and chemotherapy as independent OS risk factors. CS analysis showed that the 5-year survival probability progressively increased from 16% to 48%, 67%, 83%, and 93% after surviving 0, 1, 2, 3, and 4 years post-diagnosis. The dynamic nomogram showed excellent performance in predicting survival and stratifying patients into risk groups. Conclusions: This study provided valuable insights into the epidemiology, prognosis, and survival outcomes of EATL. The increasing incidence and CS outcomes highlighted the importance of early detection and intervention. The dynamic nomogram model developed here offered a more accurate prediction of individual survival outcomes and can aid in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.